Paul Miller
Pasadena, CANPI 1518166727
Payments from drug & device makers
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
$925,537in research payments, 2019–2025
Across 113 payments — averaging $8190.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$640K
- Sage Therapeutics, LLC$85K
- Janssen Research & Development, LLC$61K
- AbbVie$57K
- Boehringer Ingelheim$43K
- Alkermes, Inc.$39K
- plus $83 from 1 others
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.